UNSPSC 51262100: Adrenergic blocking agent indoles

This classification denotes adrenergic blocking agents made from benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.

UNSPSC 51262100 Adrenergic blocking agent indoles is a Class code that encompasses pharmaceutical products including naloxone and related therapeutic agents procured by state and local health agencies. The recent solicitation activity under this code reflects purchases of naloxone kits and drug deactivation systems by county health departments supporting community health and opioid-response initiatives, though the code's nominal scope as a pharmaceutical ingredient classification does not fully align with the actual procurement of finished medical products and systems being bought today. State and local health agencies—particularly county health departments and state health and human services commissions—are the primary issuing bodies under this code, with procurements driven by public health mandates and emergency preparedness requirements. The work solicited includes supply contracts for finished naloxone units, related drug-management systems, and pharmacy benefit program administration services. Vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify eligibility verification, and appropriate insurance coverage; procurement may incorporate federal funding streams such as FEMA, introducing additional regulatory requirements.

Recent activity concentrates in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026, and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs supporting Therapeutic Pharmacy Initiative implementation. The naloxone-focused IFB represents established commodity procurement with defined volumes and delivery schedules; the Texas RFI signals exploratory stage market research that may lead to larger formal RFPs for pharmacy benefit administration services. No set-aside designations were specified in either opportunity.